| Title |
The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial
|
|---|---|
| Published in |
Trials, December 2014
|
| DOI | 10.1186/1745-6215-15-489 |
| Pubmed ID | |
| Authors |
Claudia Sommerer, Matthias Schaier, Christian Morath, Vedat Schwenger, Geraldine Rauch, Thomas Giese, Martin Zeier |
| Abstract |
Adequate monitoring tools are required to optimise the immunosuppressive therapy of an individual patient. Particularly, in calcineurin inhibitors, as critical dose drugs with a narrow therapeutic range, the optimal monitoring strategies are discussed in terms of safety and efficacy. Nevertheless, no pharmacokinetic monitoring markers reflect the biological activity of the drug. A new quantitative analysis of gene expression was employed to directly measure the functional effects of calcineurin inhibition: the transcriptional activities of the nuclear factor of activated T-cell (NFAT)-regulated genes in the peripheral blood. |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 16% |
| Student > Ph. D. Student | 5 | 14% |
| Student > Postgraduate | 4 | 11% |
| Student > Master | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 8 | 22% |
| Unknown | 9 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 35% |
| Economics, Econometrics and Finance | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 5 | 14% |
| Unknown | 12 | 32% |